The development of light therapy in psychiatry is closely intertwined with the original description of the syndrome of seasonal affective disorder. Two decades ago, Rosenthal and colleagues (1) described a series of patients with histories of recurrent depressions that developed in the fall or winter and spontaneously remitted during the following spring or summer. Their initial report also included preliminary findings indicating that bright artificial light, administered in a manner that would in essence extend the photoperiod, was more effective than dim light in treating seasonal affective disorder. The article presented an underlying hypothesis about the pathophysiology of the syndrome (i.e., depressogenic effects of melatonin), which in turn shaped the selection of treatment parameters: the intensity, duration, and timing of bright light exposure were designed to suppress the release of melatonin and lengthen the photoperiod.
Both seasonal affective disorder and bright light therapy quickly captured considerable attention, both in the scientific community and with the general public. Several research groups launched clinical trial programs, and soon this experimental treatment was extended to other conditions, including nonseasonal mood disorders, Alzheimer’s disease, circadian-related sleep disorders and jet lag, eating disorders, and other behavioral syndromes (2, 3). An international organization (the Society for Light Treatment and Biological Rhythms) was created, and several journals that emphasized phototherapy and biological rhythms emerged. Despite the growth in clinical and research programs, there remained an absence of recognition and support for light therapy within many segments of the psychiatric treatment community. Most insurers do not offer reimbursement for this treatment, most residency training programs do not provide clinical training in phototherapy, and there is a sense that "the biological psychiatry establishment has regarded light therapy with a certain disdain and relegated it to the edge of the paradigm" (4).
The American Psychiatric Association (APA) Council on Research requested that the APA Committee on Research on Psychiatric Treatments use the principles of evidence-based medicine to examine the efficacy of light therapy (J. Greden, personal communication). A work group was formed from members of the committee as well as outside consultants with expertise and experience in relevant disciplines. The work group completed a comprehensive literature review and meta-analyses. This report contains our findings about the efficacy of light therapy in the treatment of mood disorders in adult patients.
We searched PubMed for medical literature published from Jan. 1, 1975, to July 25, 2003. The search terms included "phototherapy" (which was the original term applied to light therapy) and any of the following terms: 1) "seasonal affective disorder"; 2) "depressive disorder"; 3) "bipolar disorder"; 4) "sleep" or "sleep disorder"; 5) "circadian rhythm" or "jet lag" or "melatonin"; 6) "Alzheimer’s disease" or "dementia"; 7) "premenstrual dysphoric disorder" or "premenstrual syndrome" or "late luteal phase dysphoric disorder"; 8) "eating disorder" or "bulimia" or "obesity"; 9) "serotonin"; and 10) "attention" or "vigilance" or "reaction time." We limited our search strategy to clinical trials reported in English. We supplemented these sources by using the same search terms in MEDLINE, searching the Cochrane Collaboration Library, and searching the bibliographies of prior reviews and relevant original articles. In this article, we present our findings for studies of light therapy for mood disorders.
Study groups were limited to adults who met a criterion-based mood disorder diagnosis. We restricted the age range to 18–65 years in an effort to define a standard for adequate treatment. We recognized that at each end of the age spectrum, the requirements for light therapy dosing may differ. For example, children and adolescents may differ from adults in the needed dose of light therapy, while elderly patients may require a higher dose of photons given the normal age-related clouding of the lens and ocular media, as well as possible reduction in the number of retinal photoceptors in that population. Accepted criterion standards were DSM-III, DSM-III-R, DSM-IV, the Research Diagnostic Criteria (5), and the Rosenthal criteria (1). Subsyndromal diagnoses were excluded.
The included studies were required to be randomized, controlled trials of patients in the acute phase of treatment and to have a credible placebo control condition. Defining a minimum treatment dose (lux by time) for the experimental bright light treatment intervention was complicated by the absence of an accepted standard definition of adequate dosing. In some studies, we found that the "placebo condition" consisted of light exposure that was greater than that for the "active condition" in other studies. After we reviewed standard textbooks and consulted with expert clinicians in the field, we arrived at a priori definitions of adequate light therapy dose and duration. For bright light treatment of seasonal affective disorder, the definition was a minimum of 4 days of at least 3,000 lux-hours (e.g., 1,500 lux for 2 hours or 3,000 lux for 1 hour). We required placebo comparison groups to receive a maximum of 300 lux. For dawn simulation studies, we required that the active intervention consist of increasing light exposure from 0 to 200–300 lux over 1.0–2.5 hours and that the placebo condition consist of an increase that was less than 5 lux and/or less than 15 minutes in duration. For studies of bright light augmentation, we applied the same minimum lux criteria as those for bright light treatment of seasonal affective disorder and required that bright light therapy was the primary adjunct to the standard treatment under investigation.
We required that the outcomes be psychiatric symptom measures, e.g., Hamilton Depression Rating Scale, Seasonal Affective Disorders Version (6). Studies were excluded if gross protocol violations occurred (e.g., the study design was changed during the course of the trial).
Selection of the studies for inclusion involved two steps. First, two authors (R.N.G. and B.N.G.) independently reviewed the abstracts of all articles identified by the literature searches and excluded those for which they agreed that the eligibility criteria were not met. Next, the remaining articles were abstracted in detail (as described in the following) and the two authors made a final decision about inclusion or exclusion by consensus.
A total of 173 articles were identified and reviewed according to the selection criteria. This first step produced potentially relevant articles reporting 64 randomized, controlled trials (F1). Of these, 50 involved patients with seasonal affective disorder and 14 involved patients with other depressive illnesses. These 64 trials received detailed abstraction, including clarification of subject group and selection, study design characteristics, and intervention parameters, to determine final eligibility. In addition, baseline demographic information and psychiatric outcome data were collected to allow direct comparisons of the experimental and control groups.
All studies meeting the inclusion criteria were grouped by disorder and treatment type to produce four categories: bright light for seasonal affective disorder, bright light for nonseasonal depression, dawn simulation for seasonal affective disorder, and bright light as adjunctive treatment combined with conventional antidepressant pharmacotherapy for nonseasonal depression. The statistical information required for inclusion of a trial consisted of the mean score and standard deviation on a psychiatric symptom outcome measure and the number of subjects for each treatment condition; a trial was also included if the report contained sufficient information from which we could calculate the preceding data. For the articles in which the reported statistical detail was inadequate to allow meta-analytic procedures, several attempts were made to contact the corresponding author to gain access to the necessary raw data. For articles presenting outcomes from several treatment or control conditions, we pooled and analyzed the resulting statistics within conditions in order to use the largest study group available.
We employed standard meta-analytical methods, as described by Lipsey and Wilson (7). For each study, the standardized mean difference effect size and its 95% confidence interval (CI) were calculated and adjusted with the Hedges correction for small sample bias (8). For each of the four meta-analyses, the weighted mean of the component effect sizes and its 95% CI was calculated with the inverse variance weights from each study. The statistical significance of each weighted mean effect size was tested nondirectionally at the 0.05 level by using the z test.
If the number of subjects was sufficient, we performed homogeneity analyses of our results. If the required data were available, we calculated odds ratios for the likelihood of remission, defined a priori as a final score on the Hamilton Depression Rating Scale of 8 or less. We also applied the Q test, which uses the chi-square distribution to test the homogeneity of effect sizes across studies.
Only 23 of the 173 studies identified during our literature search met our selection criteria (F1). Of these, 20 distinct articles had sufficient data to allow inclusion in our meta-analysis (t1). One article (18) appeared to include a subset of patients who had been the subjects in a trial reported earlier (28), so the latter paper was excluded from this analysis. An additional report (9) contained the results of two experiments, one involving light therapy and another involving dawn simulation. Each was included in the appropriate, separate meta-analysis.
The results of the meta-analyses are shown in t2. We demonstrated significant effect sizes for bright light treatment of seasonal affective disorder (F2), dawn simulation for seasonal affective disorder (F3), and bright light treatment of nonseasonal depression (F4). The effect size for bright light as an adjunctive treatment for nonseasonal depression was not significant (F5).
Homogeneity analysis of the eight studies of bright light treatment of seasonal affective disorder was performed (for the other three meta-analyses, the number of studies was not large enough to support a Q test). The Q test indicated significant (p<0.0001) heterogeneity among studies; however, the effect sizes were consistently positive.
Odds ratios and their 95% CIs were calculated for the subset of four studies of bright light treatment of seasonal affective disorder for which the number of subjects who experienced remission was known. The summary estimate of risk of remission given treatment was an odds ratio of 2.9 (95% CI=1.6 to 5.4). The four study-specific odds ratios were significantly heterogeneous (p<0.04) but consistently positive.
In our literature review, we found that most of the published research reports on the effects of light therapy in mood disorders did not meet recognized criteria for rigorous clinical trial design. There are several potential explanations for this observation. First, there are inherent challenges in creating an acceptable placebo (or even an active control) condition for light therapy. While it is relatively easy to create a placebo pill or capsule that is identical in appearance to an active medication formulation, it is more difficult to "blind" a subject when broad-spectrum intense white light is the active experimental intervention. The pharmaceutical industry, which has considerable resources devoted to research and development activities, funds much of the clinical trial research for potential new antidepressant pharmacotherapies. In contrast, there has not been a similarly endowed industry nor as sizable a market in place to support the development and testing of light therapy treatments. The history of the development of light therapy, which is inextricably interwoven with the development of the concept of seasonal affective disorder, not surprisingly was dominated in its early stages by a series of relatively small, investigator-initiated pilot projects. These researchers did not have access to resources of the magnitude of those available when pharmaceutical companies seek recognition by the U.S. Food and Drug Administration of the safety and efficacy of a new medication. Unfortunately, a consensus about standard approaches to study design issues (such as lux parameters for the active treatment, duration of an adequate light therapy trial, and characteristics of placebo control conditions) was not established in the early years of light therapy research. In too many cases, high standards of research design (such as random assignment to treatment conditions, adequate reporting of results statistics) were not followed. Not surprisingly, these conditions produced inconsistencies in the research literature. We found substantial variability in the selection of study groups and in the doses of both the active and control interventions for those trials meeting our selection criteria.
All of these factors have limited the conclusions that can be drawn from light therapy research. Past efforts to synthesize the available body of literature have been as challenging as the proverbial comparison of apples and oranges. More important, the limitations in much of the literature on light therapy research may have created the unsubstantiated impression that the treatment itself has limitations in terms of its efficacy.
When we analyzed the data from all available randomized, controlled trials that met our a priori standards, we demonstrated a significant reduction in depression symptom severity following bright light therapy in seasonal affective disorder and in nonseasonal depression, as well as a significant effect with dawn simulation in seasonal affective disorder. In other words, when the "noise" from unreliable studies is removed, the effects of light therapy are comparable to those found in many antidepressant pharmacotherapy trials (29).
Earlier reviews of light therapy yielded similar findings. Terman et al. (30) pooled data from 14 research groups that collectively studied 332 patients who received bright light therapy for seasonal affective disorder over a 5-year period, and they applied a pooled clustering technique in their analysis. Twenty-nine data sets were included. Unfortunately, the vast majority were not available for inclusion in our current analysis, because they consisted of personal communications, unpublished posters presented at meetings, and book chapters, as well as a few additional reports that did not meet our inclusion criteria. Thus, only two of their 29 data sets overlap with the 20 studies included in our meta-analyses, i.e., two studies by Rosenthal et al. (1, 12). Terman et al. (30) found that 2,500-lux light exposure for at least 2 hours/day for 1 week resulted in significantly more remission when administered in the early morning than in the evening or at midday. Treatments at each of these three administration times were significantly more effective than control treatments with dim light. Tam et al. (31) concluded that bright light therapy that utilized at least 2,500-lux white light for 2 hours/day and treatment with 10,000 lux for 30 minutes/day had comparable response rates and that both treatments were efficacious. They noted that more studies were needed before conclusions could be drawn about the efficacy of dawn simulation. They highlighted the methodological limitations of the literature, which included brief treatment periods, small study groups, and lack of replication.
Several caveats and limitations in our review and analyses should be noted. First, we limited our focus to efficacy and did not study the other key feature of all treatments, safety. Very few reports of the controlled studies contained data on side effects or toxicity. Several side effects of bright light therapy have been described elsewhere, including headache, eye strain, nausea, and agitation (32, 33). To our knowledge, there have been no reports to date of retinal toxicity in association with bright light treatment, and a 5-year follow-up study showed no adverse ocular effects (34). However, some psychotropic medications may increase photosensitivity, and further study of potential adverse effects of combined pharmacotherapy and light therapy is indicated. Light therapy, like other antidepressants, may be associated with a switch to hypomania or mania in vulnerable bipolar patients (35). Other rare potential side effects from bright light treatment may emerge only after the treatment has become more widely applied. Thus, any potential recommendation of light therapy for mood disorders, based on findings of efficacy in our meta-analyses, must be tempered by the acknowledgment that safety must also be considered. This important aspect of light therapy merits careful examination with additional long-term follow-up studies.
Another limitation in this study, as described in our methods section, is that we restricted our analyses to studies of a relatively homogeneous, clearly defined population (i.e., nongeriatric adult patients). There are published reports of light therapy for seasonal affective disorder in children (e.g., references 36 and 37) and for mood disorders in the elderly (38). These important patient populations merit separate consideration, and there is a need for a larger evidence base in these areas. An additional potential application of light therapy lies in the treatment of depression during pregnancy and in the postpartum period, when safe and effective alternatives to pharmacotherapy without potential toxicity for the fetus or newborn would be clearly desirable (39, 40). It should be noted that all of the studies of dawn simulation in our meta-analysis came from a single research group, and confirmation of their findings by others at different locations would be especially important in determining the generalizability of their results. Finally, by setting a reasonably high standard for study inclusion in our meta-analysis, we excluded many of the published reports in this area. One could argue, as Smith et al. (41) did in another context, that many small, "imperfect" studies can "converge on a true conclusion." However, we agree with those who believe that meta-analyses based on flawed studies are not useful and that some bodies of data are inadequate for supporting a proper meta-analysis (42).
This study suggests that certain types of light therapy are effective in the treatment of seasonal affective disorder and other forms of depression. Much of the available literature is limited in terms of study design, and additional randomized, controlled trials with appropriate numbers of subjects are needed. Remaining questions of efficacy, safety, optimum dose, and the proper place of light therapy in the psychiatrist’s toolbox may be answered only after investigators in the field define and consistently adhere to standard approaches to essential components, such as definitions of acceptable parameters for active treatment and control conditions.
Presented in part at the 156th annual meeting of the American Psychiatric Association, San Francisco, May 17–22, 2003. Received Feb. 18, 2004; revision received April 27, 2004; accepted May 26, 2004. From the Department of Psychiatry, University of North Carolina at Chapel Hill; and the Committee on Research on Psychiatric Treatments, American Psychiatric Association, Arlington, Va. Address correspondence and reprint requests to Dr. Golden, Department of Psychiatry, Campus Box 7160, University of North Carolina at Chapel Hill, Chapel Hill, NC 27599-7160; email@example.com (e-mail).
Selection of Studies for Meta-Analysis of Trials of Light Therapy for Mood Disorders
Effect Sizes in Studies of Treatment of Seasonal Affective Disorder With Bright Light
Effect Sizes in Studies of Treatment of Seasonal Affective Disorder With Dawn Simulation
Effect Sizes in Studies of Treatment of Nonseasonal Depression With Bright Light
Effect Sizes in Studies of Treatment of Nonseasonal Depression With Bright Light as Adjunctive Treatment